AbbVie’s Etentamig Multiple Myeloma Trial Meets Both Primary Endpoints in Phase 3 CERVINO Study
AbbVie’s Phase 3 CERVINO trial shows etentamig, an investigational BCMA x CD3 bispecific, significantly improved response rate and progression-free survival versus standard therapies in relapsed/refractory multiple myeloma.
